Blood:肝素诱导性血小板减少症快速准确诊断的新算法!

2020-01-23 QQY MedSci原创

及时确诊肝素诱导性血小板减少症(HIT)对指导初始患者的治疗至关重要。在本研究中,研究人员评估了三组检测抗PF4/肝素抗体的免疫测定法的性能,进而推到出了一种短分析周转时间(TAT)的诊断算法,并对其进行了前瞻性的验证。采用Zymutest-HIA-IgG、HemosIL-AcuStar-HIT-IgG和ID-H/PF4-PaGIA对回顾性队列(221人)和前瞻性队列(305人)的血浆样本进行分析

及时确诊肝素诱导性血小板减少症(HIT)对指导初始患者的治疗至关重要。在本研究中,研究人员评估了三组检测抗PF4/肝素抗体的免疫测定法的性能,进而推到出了一种短分析周转时间(TAT)的诊断算法,并对其进行了前瞻性的验证。

采用Zymutest-HIA-IgG、HemosIL-AcuStar-HIT-IgG和ID-H/PF4-PaGIA对回顾性队列(221人)和前瞻性队列(305人)的血浆样本进行分析系。最终,研究人员建立了一种基于Bayesian的诊断算法,该算法结合了一线和二线免疫检测的前测概率和LR。

HIPA阳性的100% PPV的cut-off为>3.0 U/ml(HemosIL-AcuStar-HIT-IgG),滴定度≥16(ID-H/PF4-PaGIA);100% NPV的cut-off分别是<0.13 U/ml和≤1。

在前瞻性验证队列(687人)中,566人(82.4%)采用HemosIL-AcuStar-HIT-IgG作为唯一的检测方法(分析TAT 30分钟)。在121/687例未解决的病例中(17.6%),ID-H/PF4-PaGIA用作二线检测方法(额外TAT 30分钟)。

在687位患者中,该算法精准预测了51例HIT(7.4%),排除了604位患者(87.9%),仅有20位(2.9%)未解决。此外,该算法还鉴定出了12例(1.7%)HIPA未检测出的阳性预测:10位患者为疑似HIT,2位为假阳性。

将检测前概率与抗PF4/肝素抗体的一线和二线免疫测定相结合可在60分钟内精确的鉴定出HIT或排除HIT,准确率高达95%。

该诊断方法提高了疑诊HIT患者的初始管理

原始出处:

Matteo Marchetti, et al.Rapid and Accurate Bayesian Diagnosis of Heparin-induced thrombocytopenia.Blood.JANUARY 16, 2020

本文系williamhill asia 医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813266, encodeId=c20218132665e, content=<a href='/topic/show?id=92b5918e845' target=_blank style='color:#2F92EE;'>#诱导性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91878, encryptionId=92b5918e845, topicName=诱导性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Wed May 27 03:56:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664481, encodeId=62a7166448126, content=<a href='/topic/show?id=782d81338b9' target=_blank style='color:#2F92EE;'>#肝素诱导性血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81338, encryptionId=782d81338b9, topicName=肝素诱导性血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e13125772370, createdName=ms1756883563247400, createdTime=Sun Feb 16 14:56:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943195, encodeId=f0e41943195f7, content=<a href='/topic/show?id=0abe585885c' target=_blank style='color:#2F92EE;'>#新算法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58588, encryptionId=0abe585885c, topicName=新算法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 22 17:56:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378477, encodeId=d1193e8477ed, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jan 24 20:26:55 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302834, encodeId=22fc130283416, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 24 15:56:00 CST 2020, time=2020-01-24, status=1, ipAttribution=)]
    2020-05-27 wgx306
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813266, encodeId=c20218132665e, content=<a href='/topic/show?id=92b5918e845' target=_blank style='color:#2F92EE;'>#诱导性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91878, encryptionId=92b5918e845, topicName=诱导性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Wed May 27 03:56:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664481, encodeId=62a7166448126, content=<a href='/topic/show?id=782d81338b9' target=_blank style='color:#2F92EE;'>#肝素诱导性血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81338, encryptionId=782d81338b9, topicName=肝素诱导性血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e13125772370, createdName=ms1756883563247400, createdTime=Sun Feb 16 14:56:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943195, encodeId=f0e41943195f7, content=<a href='/topic/show?id=0abe585885c' target=_blank style='color:#2F92EE;'>#新算法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58588, encryptionId=0abe585885c, topicName=新算法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 22 17:56:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378477, encodeId=d1193e8477ed, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jan 24 20:26:55 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302834, encodeId=22fc130283416, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 24 15:56:00 CST 2020, time=2020-01-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813266, encodeId=c20218132665e, content=<a href='/topic/show?id=92b5918e845' target=_blank style='color:#2F92EE;'>#诱导性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91878, encryptionId=92b5918e845, topicName=诱导性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Wed May 27 03:56:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664481, encodeId=62a7166448126, content=<a href='/topic/show?id=782d81338b9' target=_blank style='color:#2F92EE;'>#肝素诱导性血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81338, encryptionId=782d81338b9, topicName=肝素诱导性血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e13125772370, createdName=ms1756883563247400, createdTime=Sun Feb 16 14:56:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943195, encodeId=f0e41943195f7, content=<a href='/topic/show?id=0abe585885c' target=_blank style='color:#2F92EE;'>#新算法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58588, encryptionId=0abe585885c, topicName=新算法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 22 17:56:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378477, encodeId=d1193e8477ed, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jan 24 20:26:55 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302834, encodeId=22fc130283416, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 24 15:56:00 CST 2020, time=2020-01-24, status=1, ipAttribution=)]
    2020-07-22 lisa438
  4. [GetPortalCommentsPageByObjectIdResponse(id=1813266, encodeId=c20218132665e, content=<a href='/topic/show?id=92b5918e845' target=_blank style='color:#2F92EE;'>#诱导性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91878, encryptionId=92b5918e845, topicName=诱导性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Wed May 27 03:56:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664481, encodeId=62a7166448126, content=<a href='/topic/show?id=782d81338b9' target=_blank style='color:#2F92EE;'>#肝素诱导性血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81338, encryptionId=782d81338b9, topicName=肝素诱导性血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e13125772370, createdName=ms1756883563247400, createdTime=Sun Feb 16 14:56:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943195, encodeId=f0e41943195f7, content=<a href='/topic/show?id=0abe585885c' target=_blank style='color:#2F92EE;'>#新算法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58588, encryptionId=0abe585885c, topicName=新算法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 22 17:56:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378477, encodeId=d1193e8477ed, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jan 24 20:26:55 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302834, encodeId=22fc130283416, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 24 15:56:00 CST 2020, time=2020-01-24, status=1, ipAttribution=)]
    2020-01-24 qingfengqishi5

    学习了,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1813266, encodeId=c20218132665e, content=<a href='/topic/show?id=92b5918e845' target=_blank style='color:#2F92EE;'>#诱导性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91878, encryptionId=92b5918e845, topicName=诱导性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Wed May 27 03:56:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664481, encodeId=62a7166448126, content=<a href='/topic/show?id=782d81338b9' target=_blank style='color:#2F92EE;'>#肝素诱导性血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81338, encryptionId=782d81338b9, topicName=肝素诱导性血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e13125772370, createdName=ms1756883563247400, createdTime=Sun Feb 16 14:56:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943195, encodeId=f0e41943195f7, content=<a href='/topic/show?id=0abe585885c' target=_blank style='color:#2F92EE;'>#新算法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58588, encryptionId=0abe585885c, topicName=新算法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 22 17:56:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378477, encodeId=d1193e8477ed, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jan 24 20:26:55 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302834, encodeId=22fc130283416, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 24 15:56:00 CST 2020, time=2020-01-24, status=1, ipAttribution=)]

相关威廉亚洲官网

Blood:口服抗凝药对肝素诱导性血小板减少症的疗效

肝素诱导性血小板减少症(HIT)发生在临床上应用肝素治疗后诱发血小板减少,其发病机制可能与免疫机制有关。根据病程进展,可以分为暂时性血小板减少和持久性血小板减少,表现为血小板减少,同时可伴随血栓形成和弥散性血管内凝血。

HIT证书“值”多少?

医院信息化建设日益深化,各方都在寻求一个权威的认证来检测医院信息系统的效能,但是,这种认证“值”多少呢?

Chest:静脉注射免疫球蛋白治疗严重难治性肝素诱发的血小板减少症!

这些研究表明,对标准疗法无效且伴有严重疾病的HIT患者应考虑IVIg治疗。

Circulation:心脏移植术后一年内开展高强度的间歇性运动可改善预后

心脏移植(HTx)后,如何、何时可开展何种强度的运动,目前尚无共识。Kari Nytr?en等人发现,在HTx后的维持状态下,高强度间歇性训练(HIT)是安全的、耐受良好的、有效的,但尚不明确HIT是否适用于刚进行过HTx的患者。研究人员开展一多中心的前瞻性随机对照试验,招募了81位HTx后平均11周(7-16周)的患者。将患者按1:1随机分至9个月的HIT组(最大努力的85%-95%,4x4mi

中华内科杂志:肝素诱导的血小板减少症发病率及其抗体阳性率调查

中日友好医院血液科高亚玥和中国医学科学院北京协和医学院北京协和医院住院赵永强、王书杰探讨了患者肝素诱导的血小板减少症(HIT)发病率和HIT抗体阳性率及相关临床因素。结果表明,肝素制剂应用人群中HIT的发病率和HIT抗体阳性率不低,且均与病种有关。HIT抗体检测在4Ts评分高可能性患者中的临床应用价值更大。相关论文发表于2013年第9期《中华内科杂志》。 研究者们选取了应用肝素制剂的患者